WEXFORD,
Pa., Oct. 15, 2024 /PRNewswire/ -- Coeptis
Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or
"Coeptis"), a biopharmaceutical company developing innovative cell
therapy platforms for cancer, autoimmune, and infectious diseases,
announced that its Chief Scientific and Medical Officer
Colleen Delaney, MD will attend and
present at the following upcoming fall conferences. These events,
including the 2024 AABB Annual Meeting, the 50th ASHI Annual
Meeting, the Advanced Therapies USA Congress, and the Donor Selection &
Cell Source Summit, offer an opportunity to expand awareness of
Coeptis' advancements in universal cell therapy and its potential
to transform patient outcomes.
Upcoming Conferences:
Event: 2024 AABB
Annual Meeting
Date:
October 19-22, 2024
Location:
George R. Brown Convention Center, Houston, TX
Event:
ASHI 50th Annual Meeting
Date:
October 21-24, 2024
Location:
Marriott Anaheim, Anaheim, CA
Event:
Advanced Therapies USA
Congress
Date:
November 12-13, 2024
Location:
Pennsylvania Convention Center,
Philadelphia, PA
Event:
Donor Selection & Cell Source Summit
Date:
November 18-20, 2024
Location:
DoubleTree by Hilton Hotel San Diego, San
Diego, CA
Dave Mehalick, President and CEO
of Coeptis Therapeutics commented, "Attending these high-profile
conferences will provide us with an essential platform to build
momentum for our work in universal cell therapy. At Coeptis, our
focus is on delivering off-the-shelf universal allogeneic
therapies, with the goal of revolutionizing cell therapy by
dramatically lowering treatment costs and improving access to
life-saving therapies for patients with cancer and other critical
diseases. These events present a unique opportunity to connect with
industry leaders, researchers, and decision-makers in fields that
are critical to making our treatments universally accessible,
scalable, and safe for all patients."
About Coeptis Therapeutics Holdings, Inc.
Coeptis
Therapeutics Holdings, Inc., together with its subsidiaries
including Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals,
Inc., (collectively "Coeptis"), is a biopharmaceutical company
developing innovative cell therapy platforms for cancer,
autoimmune, and infectious diseases that have the potential to
disrupt conventional treatment paradigms and improve patient
outcomes. Coeptis' product portfolio and rights are highlighted by
assets licensed from Deverra Therapeutics, including an allogeneic
cellular immunotherapy platform and DVX201, a clinical-stage,
unmodified natural killer cell therapy technology. Additionally,
Coeptis is developing a universal, multi-antigen CAR T technology
licensed from the University of
Pittsburgh (SNAP-CAR), and the GEAR cell therapy and
companion diagnostic platforms, which Coeptis is developing with
VyGen-Bio and leading medical researchers at the Karolinska Institutet. Coeptis' business model is
designed around maximizing the value of its current product
portfolio and rights through in-license agreements, out-license
agreements and co-development relationships, as well as entering
into strategic partnerships to expand its product rights and
offerings, specifically those targeting cancer and infectious
diseases. The Company is headquartered in Wexford, PA. For more information on Coeptis
visit https://coeptistx.com/.
Cautionary Note Regarding Forward-Looking
Statements
This press release and statements of our
management made in connection therewith contain or may contain
"forward-looking statements" (as defined in Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended). Forward-looking
statements include statements concerning our plans, objectives,
goals, strategies, future events or performance, and underlying
assumptions, and other statements that are other than statements of
historical facts. When we use words such as "may," "will,"
"intend," "should," "believe," "expect," "anticipate," "project,"
"estimate" or similar expressions that do not relate solely to
historical matters, we are making forward-looking statements.
Forward-looking statements are not a guarantee of future
performance and involve significant risks and uncertainties that
may cause the actual results to differ materially and perhaps
substantially from our expectations discussed in the
forward-looking statements. Factors that may cause such differences
include but are not limited to: (1) the inability to maintain the
listing of the Company's securities on the Nasdaq Capital Market;
(2) the risk that the integration of the Deverra licensed assets
will disrupt current plans and operations of the Company; (3) the
inability to recognize the anticipated benefits of the
newly-licensed assets, which may be affected by, among other
things, competition, the ability of the Company to grow and manage
growth economically and hire and retain key employees; (4) the
risks that the Company's products in development or the
newly-licensed assets fail clinical trials or are not approved by
the U.S. Food and Drug Administration or other applicable
regulatory authorities; (5) costs related to integrating the
newly-licensed Deverra assets and pursuing the contemplated asset
development paths; (6) changes in applicable laws or regulations;
(7) the possibility that the Company may be adversely affected by
other economic, business, and/or competitive factors; and (8) the
impact of the global COVID-19 pandemic on any of the foregoing
risks and other risks and uncertainties identified in the Company's
filings with the Securities and Exchange Commission (the "SEC").
The foregoing list of factors is not exclusive. All forward-looking
statements are subject to significant uncertainties and risks
including, but not limited, to those risks contained or to be
contained in reports and other filings filed by the Company with
the SEC. For these reasons, among others, investors are cautioned
not to place undue reliance upon any forward-looking statements in
this press release. Additional factors are discussed in the
Company's filings made or to be made with the SEC, which are
available for review at www.sec.gov. We undertake no obligation to
publicly revise these forward-looking statements to reflect events
or circumstances that arise after the date hereof unless required
by applicable laws, regulations, or rules.
Contacts
Coeptis Therapeutics, Inc.
IR@coeptistx.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/coeptis-therapeutics-chief-scientific-and-medical-officer-to-present-at-upcoming-fall-conferences-highlighting-progress-in-universal-cell-therapy-302274688.html
SOURCE Coeptis Therapeutics, Inc.